Wyeth’s International OTC Growth Offsets Drop In U.S. Robitussin Sales
This article was originally published in The Tan Sheet
Sales of Wyeth's OTC products increased 10.4 percent worldwide in its fiscal 2008 first quarter despite a 14.2 percent drop in sales of its Robitussin cough/cold products, the firm says
You may also be interested in...
Wyeth Consumer Healthcare is voluntarily recalling and replacing Children's Dimetapp Cold & Chest Congestion and multiple products in its Robitussin line because the products' dosing cups are not marked with half-teaspoon units, the recommended dose for children ages 2 to 6, the firm said Oct. 29
Manufacturers of OTC cough/cold medicines for children under 2 years old are voluntarily withdrawing the products from the market due to potential misuse, not from product safety concerns, the Consumer Healthcare Products Association said Oct. 11
Granger’s exit means House Appropriations will have different chair no matter which party wins majority 2024 elections; Democrats will lose senior House Energy and Commerce Health Subcommittee member with Eshoo’s retirement.